Efficacy and Safety of 4-Weekly Docetaxel for Castration-Resistant Prostate Cancer

Abstract

We investigated the efficacy and safety profiles of 4-weekly docetaxel for castration-resistant prostate cancer. Patients treated with ≥2 courses of docetaxel chemotherapy (median, 70 mg/m²) between 2008 and 2018 were included. Among 125 Japanese men, 40 (32.0%) and 85 (68.0%) were treated with 3-weekly and 4-weekly regimens, respectively. In the 4-weekly regimen, the risks of progression, treatment failure, and any-cause mortality were comparable to those in the 3-weekly regimen. The incidences of severe adverse events were also similar between the 3-weekly and 4-weekly regimens. These data suggest that the 4-weekly regimen may be an acceptable option for selected patients.

Keywords:

• Castration-resistant prostate cancer
• docetaxel
• treatment schedule
• adverse event

Acknowledgments

The authors thank Nicole Okoh, PhD, from Edanz Group (https://en-author-services.edanzgroup.com/) for editing a draft of this manuscript.

Disclosure statement

No potential conflict of interest was reported by the author(s).